Abstract
Das Nebennierenkarzinom (ACC, NN-Karzinom) ist eine seltene Erkrankung mit schlechter Prognose. Präoperativ ist eine sorgfältige Hormondiagnostik obligat, da der Hormonstatus das perioperative Management beeinflusst, und um Tumormarker für die Nachsorge zu etablieren. In der Bildgebung sind CT und MRT gleichwertig, wobei für die Differenzierung zwischen benignen und malignen Raumforderungen die Bestimmung des Fettgehalts der Läsion und das Kontrastmittel-Wash-out nach 10 min von großer Bedeutung sind. Der einzig kurative Ansatz besteht in der kompletten chirurgischen Resektion mittels offener Adrenalektomie (in der Regel über einen lateralen oder thorakoabdominellen Zugang). Eine intraoperative Kapselverletzung ist dabei unbedingt zu vermeiden. Allerdings sind auch nach R0-Resektion Rezidive sehr häufig, sodass regelmäßige Nachsorgeuntersuchungen über mindestens 5 Jahre notwendig sind. Bei fortgeschrittenem Nebennierenkarzinom wird eine Therapie mit Mitotane mit oder ohne Kombination mit einer Chemotherapie, vorzugsweise im Rahmen der FIRM-ACT-Studie, durchgeführt.
Abstract
Adrenocortical carcinoma (ACC) is a rare disease with poor prognosis. Preoperatively, a thorough hormonal work-up is mandatory, as the hormonal status may influence the perioperative management and may also provide marker hormones for monitoring of tumour recurrence. CT and MRI are equally sensitive and specific imaging tools for adrenal tumours. For discerning malignancy, assessment of the fat content of the tumour and contrast media wash-out after 10 min are of great value. Complete surgical resection of the tumour offers the only chance for cure. Open adrenalectomy via a flank or thoracoabdominal approach is the standard surgical technique. Intraoperative tumour spillage should be carefully avoided. Even after R0 resection, recurrence of the disease is frequent and regular follow-up for a minimum of 5 years is required. In advanced ACC, the treatment of choice is mitotane with or without cytotoxic chemotherapy (preferably after inclusion into the FIRM-ACT trial).
Literatur
Abraham J, Bakke S, Rutt A et al. (2002) A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: Continuous infusion doxorubicin, vincristin, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 94(9): 2333–2343
Allolio B, Fassnacht M (2006) Clinical review: Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 91(6): 2027–2037
Barzon L, Scaroni C, Sonino N et al. (1999) Risk factors and long-term follow-up of adrenal incidentalomas. J Clin Endocrinol Metab 84: 520–526
Berruti A, Terzolo M, Sperone P et al. (2005) Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 12: 657–666
Boland GW, Lee MJ, Gazelle GS et al. (1998) Characterization of adrenal masses in unenhanced CT: an analysis of the CT literature. AJR Am J Roentgenol 171(1): 201–204
Bonacci R, Gigliotti A, Baudin E et al. (1998) Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. Reseau Comete INSERM. Br J Cancer 78(4): 546–549
Bukowski RM, Wolfe M, Levine HS et al. (1993) Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma. J Clin Oncol 11(1): 161–165
Decker RA, Elson P, Hogan TF et al. (1991) Eastern Cooperative Oncology Group Study 1879: Mitotane and adriamycin in patients with advanced adrenocortical carcinoma. Surgery 110(6): 1006–1013
DeLellis RA, Lloyd RV, Heitz PU, Eng C (2004) World Health Organization classification of tumours. Pathology and genetics of tumours of endocrine organs. Lyon, France; IARC Press
Fassnacht M, Hahner S, Polat B et al. (2006) Adjuvant radiation therapy of the tumor bed prevents local recurrences in adrenocortical carcinoma. Exp Clin Endocrinol Diabet 114(Suppl 1): 17
Fassnacht M, Kenn W, Allolio B (2004) Adrenal tumors: how to establish malignancy? J Endocrinol Invest 27: 387–399
Grumbach MM, Biller BM, Braunstein GD et al. (2003) Management of the clinically inapparent adrenal mass („incidentaloma“). Ann Intern Med 138: 424–429
Hahner S, Fassnacht M (2005) Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs 6: 386–394
Hennings J, Lindhe Ö, Bergström M et al. (2006) [11C]Metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. J Clin Endocrinol Metab 91: 1410–1414
Honigschnabl S, Gallo S, Niederle B et al. (2002) How accurate is MR imaging in characterisation of adrenal masses: update of a long-term study. Eur J Radiol 41:113–122
Khan TS, Imam H, Juhlin C et al. (2000) Streptozocin and o,p’DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol 11:1281–1287
Kirschner LS (2006) Emerging treatment strategies for adrenocortical carcinoma: a new hope. J Clin Endocrinol Metab 91: 14–21
Koschker AC, Fassnacht M, Hahner S et al. (2006) Adrenocortical carcinoma: Improving patient care by establishing new structures. Exp Clin Endocrinol Diab 114(45): 45–51
Leboulleux S, Dromain G, Bonniaud G et al. (2006) Diagnostic and prognostic value of 18-fluorodeoxyglucose positron emission tomography in adrenocortical carcinoma: a prospective comparison with computed tomography. J Clin Endocrinol Metab 91: 920–925
Lee JE, Berger DH, el-Naggar AK et al. (1995) Surcigal management, DNA content, and patient survival in adrenal cortical carcinoma. Surgery 118: 1090–1098
NCI (1981) Surveillance, epidemiology and end results: incidence and mortality data 1973-77. Bethesda, Maryland, National Cancer Institute
Saeger W (2000) Histopathological classification of adrenal tumours. Eur J Clin Invest 30(Suppl 3): 58–62
Schlumberger M, Brugieres L, Gicquel C et al. (1991) 5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma. Cancer 67(12): 2997–3000
Schteingart DE, Doherty GM, Gauger PG et al. (2005) Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 12: 667–680
Terzolo M, Angeli, A, Fassnacht M et al. (2007) Adjuvant mitotane treatment in patients with adrenocortical carcinoma. N Engl J Med 356(23): 2372–2380
van Slooten H, van Oosterom AT (1983) CAP (cyclophosphamide, doxorubicin, and cisplatin) regimen in adrenal cortical carcinoma. Cancer Treat Rep 67(4): 377–379
Weiss LM, Medeiros LJ, Vickery AL Jr. (1989) Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol 13(3): 202–206
Williamson SK, Lew D, Miller GJ et al. (2000) Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: A Southwest Oncology Group Study. Cancer 88(5): 1159–1165
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Johanssen, S., Fassnacht, M., Brix, D. et al. Das Nebennierenkarzinom. Urologe 47, 172–181 (2008). https://doi.org/10.1007/s00120-007-1578-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00120-007-1578-0